Your browser is no longer supported. Please, upgrade your browser.
Settings
KROS [NASD]
Keros Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.27 Insider Own0.40% Shs Outstand23.23M Perf Week-2.52%
Market Cap869.22M Forward P/E- EPS next Y-3.84 Insider Trans-76.76% Shs Float18.50M Perf Month-13.35%
Income-48.50M PEG- EPS next Q-0.66 Inst Own83.50% Short Float5.04% Perf Quarter-37.41%
Sales- P/S- EPS this Y-356.80% Inst Trans0.20% Short Ratio6.50 Perf Half Y-35.50%
Book/sh10.69 P/B3.44 EPS next Y-35.20% ROA-23.80% Target Price- Perf Year20.10%
Cash/sh10.80 P/C3.41 EPS next 5Y- ROE-24.80% 52W Range28.02 - 88.80 Perf YTD-47.83%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-58.56% Beta-
Dividend %- Quick Ratio28.60 Sales past 5Y- Gross Margin- 52W Low31.33% ATR2.27
Employees38 Current Ratio28.60 Sales Q/Q- Oper. Margin- RSI (14)31.89 Volatility5.54% 5.22%
OptionableNo Debt/Eq0.00 EPS Q/Q-2.00% Profit Margin- Rel Volume0.49 Prev Close37.31
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume143.37K Price36.80
Recom1.50 SMA20-7.09% SMA50-19.58% SMA200-37.50% Volume69,808 Change-1.37%
Dec-08-20Reiterated H.C. Wainwright Buy $50 → $100
May-04-20Initiated SVB Leerink Outperform $42
May-04-20Initiated Piper Sandler Overweight $35
May-04-20Initiated Jefferies Buy $37
May-04-20Initiated H.C. Wainwright Buy $50
Jul-07-21 04:24AM  
Jun-22-21 04:01PM  
Jun-11-21 08:00AM  
May-27-21 08:00AM  
May-25-21 08:00AM  
May-14-21 08:00AM  
May-12-21 04:01PM  
May-06-21 04:01PM  
Apr-08-21 03:20AM  
Mar-25-21 08:00AM  
Mar-05-21 08:00AM  
Mar-02-21 08:00AM  
Feb-17-21 08:00AM  
Jan-25-21 02:45AM  
Dec-21-20 08:00AM  
Dec-17-20 08:00AM  
Dec-09-20 03:44PM  
Dec-08-20 04:03PM  
Dec-07-20 08:00AM  
Nov-17-20 04:01PM  
Nov-16-20 08:00AM  
Nov-12-20 10:11PM  
Nov-10-20 05:12PM  
04:17PM  
Nov-09-20 08:00AM  
Nov-04-20 04:01PM  
Oct-27-20 08:35AM  
Oct-20-20 08:00AM  
Sep-14-20 07:01AM  
Sep-11-20 04:01PM  
Aug-13-20 07:00AM  
Aug-10-20 08:00AM  
Aug-04-20 08:00AM  
Jul-29-20 10:12AM  
Jun-26-20 07:01AM  
Jun-24-20 08:34AM  
Jun-12-20 07:01AM  
May-28-20 07:01AM  
May-22-20 07:00AM  
May-14-20 09:15AM  
May-05-20 11:46AM  
Apr-13-20 04:01PM  
Apr-07-20 08:45PM  
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Knowles JuliusDirectorJul 02Sale41.3423,818984,565345,585Jul 06 06:02 PM
Knowles JuliusDirectorJul 01Sale41.2823,834983,787354,987Jul 06 06:02 PM
Lachey JenniferChief Scientific OfficerJun 24Option Exercise0.306,5001,95084,407Jun 25 06:29 PM
Ordonez ClaudiaChief Medical OfficerJun 11Option Exercise0.481,0004801,000Jun 15 05:01 PM
Lachey JenniferChief Scientific OfficerJun 11Option Exercise0.302,65079580,557Jun 15 05:02 PM
Lachey JenniferChief Scientific OfficerJun 11Sale50.982,650135,08777,907Jun 15 05:02 PM
Ordonez ClaudiaChief Medical OfficerJun 11Sale50.991,00050,9900Jun 15 05:01 PM
Knowles JuliusDirectorJun 07Sale49.8912,796638,451364,395Jun 08 04:31 PM
Knowles JuliusDirectorJun 04Sale47.466,619314,162369,446Jun 08 04:31 PM
Knowles JuliusDirectorJun 03Sale47.977,895378,730372,059Jun 03 08:06 PM
Knowles JuliusDirectorJun 02Sale48.7611,529562,138375,175Jun 03 08:06 PM
Knowles JuliusDirectorJun 01Sale52.518,812462,686379,726Jun 03 08:06 PM
Lachey JenniferChief Scientific OfficerMay 13Option Exercise0.126,72083477,907May 13 04:36 PM
Ordonez ClaudiaChief Medical OfficerMay 11Option Exercise0.481,0004801,000May 13 04:37 PM
Lachey JenniferChief Scientific OfficerMay 11Option Exercise0.302,65079573,837May 13 04:36 PM
Lachey JenniferChief Scientific OfficerMay 11Sale50.002,650132,50071,187May 13 04:36 PM
Ordonez ClaudiaChief Medical OfficerMay 11Sale50.151,00050,1500May 13 04:37 PM
Knowles JuliusDirectorMay 04Sale53.922,835152,857383,205May 05 05:22 PM
Knowles JuliusDirectorMay 03Sale57.4844,8162,575,992384,324May 05 05:22 PM
Lachey JenniferChief Scientific OfficerApr 12Option Exercise0.305,3001,59076,487Apr 14 04:43 PM
Ordonez ClaudiaChief Medical OfficerApr 12Option Exercise0.481,0004801,000Apr 14 04:46 PM
Lachey JenniferChief Scientific OfficerApr 12Sale60.005,300318,02671,187Apr 14 04:43 PM
Ordonez ClaudiaChief Medical OfficerApr 12Sale59.931,00059,9260Apr 14 04:46 PM
Knowles JuliusDirectorApr 06Sale58.819,298546,840402,015Apr 08 04:35 PM
Knowles JuliusDirectorApr 05Sale60.0727,1511,630,832405,685Apr 05 09:11 PM
Lachey JenniferChief Scientific OfficerApr 01Option Exercise0.119,9961,10071,187Apr 02 04:32 PM
Knowles JuliusDirectorApr 01Sale58.8911,202659,704416,403Apr 05 09:11 PM
Lachey JenniferChief Scientific OfficerMar 11Option Exercise0.305,3001,59066,491Mar 15 04:43 PM
Ordonez ClaudiaChief Medical OfficerMar 11Option Exercise0.481,0004801,000Mar 15 04:45 PM
Lachey JenniferChief Scientific OfficerMar 11Sale64.485,300341,75061,191Mar 15 04:43 PM
Ordonez ClaudiaChief Medical OfficerMar 11Sale64.561,00064,5560Mar 15 04:45 PM
Knowles JuliusDirectorMar 04Sale55.4811,632645,385420,825Mar 05 07:44 PM
Knowles JuliusDirectorMar 03Sale57.3612,327707,115425,417Mar 05 07:44 PM
Knowles JuliusDirectorMar 02Sale58.7510,711629,285430,283Mar 03 08:40 PM
Knowles JuliusDirectorMar 01Sale63.0912,979818,793434,511Mar 03 08:40 PM
Lachey JenniferChief Scientific OfficerFeb 26Option Exercise0.1133,2003,65261,191Mar 01 04:54 PM
Knowles JuliusDirectorFeb 18Sale63.112,944185,785439,634Feb 18 06:46 PM
Knowles JuliusDirectorFeb 17Sale61.0516,061980,588440,796Feb 18 06:46 PM
Knowles JuliusDirectorFeb 16Sale59.899,612575,671447,136Feb 18 06:46 PM
Knowles JuliusDirectorFeb 12Sale61.537,468459,495450,930Feb 16 05:50 PM
Ordonez ClaudiaChief Medical OfficerFeb 11Option Exercise0.481,0004801,000Feb 16 05:49 PM
Lachey JenniferChief Scientific OfficerFeb 11Option Exercise0.305,3001,59033,291Feb 16 05:47 PM
Knowles JuliusDirectorFeb 11Sale64.8211,561749,441453,878Feb 16 05:50 PM
Ordonez ClaudiaChief Medical OfficerFeb 11Sale64.841,00064,8410Feb 16 05:49 PM
Lachey JenniferChief Scientific OfficerFeb 11Sale64.915,300344,01727,991Feb 16 05:47 PM
Nussbaum RanDirectorNov 17Buy50.0060,0003,000,0002,288,151Nov 19 04:40 PM
Kariv TomerDirectorNov 17Buy50.0060,0003,000,0002,288,151Nov 19 04:39 PM
Pontifax Management 4 G.P. (2010% OwnerNov 17Buy50.0060,0003,000,0002,288,151Nov 19 04:38 PM